Single Dose of Bisphosphonate Preserves Gains in Bone Mass Following Cessation of Sclerostin Antibody in Brtl/+ Osteogenesis Imperfecta Model

Sclerostin antibody has demonstrated a bone-forming effect in pre-clinical models of osteogenesis imperfecta, where mutations in collagen or collagen-associated proteins often result in high bone fragility in pediatric patients. Cessation studies in osteoporotic patients have demonstrated that scler...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Bone
Main Authors: Perosky, Joseph E., Khoury, Basma M., Jenks, Terese N., Ward, Ferrous S., Cortright, Kai, Meyer, Bethany, Barton, David K., Sinder, Benjamin P., Marini, Joan C., Caird, Michelle S., Kozloff, Kenneth M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5077648/
https://ncbi.nlm.nih.gov/pubmed/27641475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2016.09.013
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados